Association of human papillomavirus 16 E6 variants with cervical carcinoma and precursor lesions in women from Southern Mexico

Julio Ortiz-Ortiz¹, Luz del Carmen Alarcón-Romero², Marco Antonio Jiménez-López³, Víctor Hugo Garzón-Barrientos³, Itzel Calleja-Macías⁴, Hugo Alberto Barrera-Saldaña⁵, Marco Antonio Leyva-Vázquez⁵ and Berenice Illades-Aguiar¹*

Abstract

Background: HPV 16 is the cause of cervical carcinoma, but only a small fraction of women with HPV infection progress to this pathology. Besides persistent infection and HPV integration, several studies have suggested that HPV intratype variants may contribute to the development of cancer. The purpose of this study was to investigate the nucleotide variability and phylogenetically classify HPV 16 E6 variants circulating over a period of 16 years in women from Southern Mexico, and to analyze its association with precursor lesions and cervical carcinoma.

Methods: This study was conducted in 330 cervical DNA samples with HPV 16 from women who were residents of the State of Guerrero, located in Southern Mexico. According of cytological and/or histological diagnosis, samples were divided into the following four groups: no intraepithelial lesion (n = 97), low-grade squamous intraepithelial lesion (n = 123), high-grade squamous intraepithelial lesion (n = 19) and cervical carcinoma (n = 91). HPV 16 E6 gene was amplified, sequenced and aligned with reference sequence (HPV 16R) and a phylogenetic tree was constructed to identify and classify HPV 16 variants. Chi squared was used and data analysis and statistics were done with SPSS Statistics and STATA softwares.

Results: Twenty seven HPV 16 E6 variants were detected in women from Southern Mexico, 82.12% belonged to the EUR, 17.58% to AA1 and 0.3% to Afr2a sublineages. The most common was E-G350 (40%), followed by E-prototype (13.03%), E-C188/G350 (11.82%), AA-a (10.61%), AA-c (6.07%) and E-A176/G350 (5.15%). Eight new E6 variants were found and 2 of them lead to amino acid change: E-C183/G350 (I27T) and E-C306/G350 (K68T). The HPV 16 variant that showed the greatest risk of leading to the development of CC was AA-a (OR = 69.01, CI = 7.57-628.96), followed by E-A176/G350 (OR = 39.82, CI = 4.11-386.04), AA-c (OR = 21.16, CI 2.59-172.56), E-G350 (OR = 13.25, CI = 2.02-87.12) and E-C188/G350 (OR = 10.48, CI = 1.39-78.92).

Conclusions: The variants more frequently found in women with cervical carcinoma are E-G350, AA-a, AA-c, E-C188/G350 and E-A176/G350. All of them are associated with the development of cervical carcinoma, however, AA-a showed the highest association. This study reinforces the proposal that HPV 16 AA-a is an oncogenic risk for cervical carcinoma progression in Mexico.

Keywords: HPV 16 variants, Cervical cancer, Precursor lesions

* Correspondence: b.illadesaguiar@gmail.com
1 Laboratorio de Biomedicina Molecular, Unidad Académica de Ciencias Químico Biológicas, Universidad Autónoma de Guerrero, Chilpancingo, Guerrero, México
Full list of author information is available at the end of the article

© 2015 Ortiz-Ortiz et al; licensee BioMed Central. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background

Infection by high risk human papillomavirus (HR-HPV) is necessary for the development of cervical carcinoma (CC) [1] and HPV 16 is the cause of more than half of CC worldwide [2]. Only a small fraction of women with HPV infection may progress to cervical carcinoma; however, the factors that favor this progression are still poorly understood. Besides persistent infection and HPV integration [3,4], several studies have suggested that HPV intratype variants may contribute to cancer development [4-7].

Like other HR-HPV, HPV 16 has well preserved distinctive intratypic variants by geographical origin [8], their global distribution and risk of cervical carcinoma appears to be dependent on the population [9,10]. Its phylogeny reflects evolutionary divergence associated with human migration patterns, suggesting that they may have co-diversified as human populations expanded worldwide [11]. HPV 16 variants have been classified into 4 major lineages and 9 sublineages based on common LCR and E6 single polymorphisms: (1) European-Asian (EAS), including European (EUR) and Asian (As) sublineages; (2) African 1 (AFR1), including Afr1a and Afr1b sublineages; (3) African 2 (AFR2), including Afr2a and Afr2b sublineages; and (4) Asian American/North American (AA/NA), including Asian American 1 (AA1), Asian American 2 (AA2) and North American (NA) sublineages [12].

Several reports have shown the presence of common polymorphisms that generate amino acid changes in the E6 oncoprotein, one of them is T350G, and is present in the four lineages. T350G causes a leucine to valine change (L83V), that leads to the split of the EUR sublineage into three classes, 350 T (prototype sequence), 350C and 350G. Other polymorphisms including A131G, G132C, C143G, G145T, G176A, T178G and C335T generate the amino acid changes R10G/I, Q14H/D, D25E/N, I27R and H78Y, respectively [13]. It has been suggested that these polymorphisms and the subsequent amino acid changes in E6 HPV 16 variants may influence the persistence of HPV infection and its progression to cervical carcinoma [4,14-18].

Epidemiologic data shows that regions with high incidence of cervical carcinoma like Latin America, Africa and Asia, also have a high prevalence of sublineages AA and Af [9]. Studies in Mexico have reported that persistent infection and risk of progression to cervical carcinoma is higher when HPV infection is caused by AA sub-lineages compared with EUR sublineages [5,19-21].

Social disparities like access to social security health care services, ethnic groups, residence and socioeconomic level are factors associated with cervical carcinoma development [22]. The State of Guerrero, located in Southern Mexico, is the second poorest state in Mexico and a majority of inhabitants have a very low socioeconomic level. In this region, cervical carcinoma is the most common type of cancer in women and has the fourth highest mortality rate in the country with 12.5 deaths per 100,000 women, compared to the national mortality rate of 9.1 per 100,000 in 2008 [23].

We have previously shown that HPV 16 was the most commonly identified HPV genotype in cervical carcinoma and high grade squamous intraepithelial lesions in women from the State of Guerrero. We studied a sample of HPV 16 positive women and found E and AA variants [24]. It has been proposed that variants AA of HPV 16 are more oncogenic than E variants [5,25].

Knowing the regional variants of HPV 16 is of great value for evolutionary, phylogenetic, epidemiological and biological analysis [13]. To further analyze the regional variants of HPV 16, the aim of this study was to investigate the nucleotide variability and phylogenetically classify HPV 16 E6 variants circulating over a period of 16 years in the Southern Mexican population, and to analyze its association with the whole spectrum of disease from no intraepithelial lesion in cervical epithelium to cervical carcinoma.

The most dominant HPV variants were detected in low and high-grade squamous intraepithelial lesion, cervical carcinoma and no intraepithelial lesion, and 8 novel HPV 16 variants were found. An association between E-G350, E-A176/G350, E-C188/G350, AA-a and AA-c variants and the risk of developing cervical carcinoma was shown in this study.

Results

HPV 16 E6 variants and phylogenetic analysis

The variant analysis for the E6 gene was carried out in 330 HPV16 samples from all study groups. Using the HPV 16 R (Los Alamos National Laboratory, http://www.ncbi.nlm.nih.gov/nuccore/NC_001526.2) as a reference sequence, a total of 27 variants were detected, 8 of them were new. Sequence analysis showed substitution in 29 nucleotides located between positions 104 and 559 in the E6 sequence with a predicted amino acid change (Table 1).

The phylogenetic analysis showed that the E6 variants found belong to EUR, AA1 and Afr2a sublineages. Six of the 8 novel variants were related to variants of the EUR sublineages, and 2 to variants of the AA1 sublineage (Figure 1). The phylogenetic classification of the E6 variants showed that the majority (82.12%) belonged to the EUR sublineage, followed by AA1 (17.58%) and Afr2a (0.3%) sublineages. From sublineage EUR, 15.45% was class E-T350 which includes E-Prototype (13.03%), and 66.67% was class E-G350 finding 19 subclasses. From sublineage AA1, AA-a class was the most frequent (10.91%) followed by AA-c class (6.67%). From the 27 variants found in this study, the most common E6 variant was E-G350 (40%), followed by E-prototype (13.03%), E-C188/G350 (11.82%), AA-a (10.61%), AA-c (6.07%) and E-A176/G350 (5.15%).
| Variants | HPV 16 E6 nucleotide position | Predicted amino acid change E6 protein (151 aa form) | Frequency |
|----------|-------------------------------|-----------------------------------------------|-----------|
| HPV 16R  | T C A G C G G A T T G A C A T T A A C C T A A A A | No change | 51 | 15.45% |
| Lineage  | EAS/Sublineage EUR | | | |
| Class E- | T350 | | | |
| E-Prototype | | | | |
| E-G131 | - G | | | |
| Class E- | G350 | | | |
| E-G350 | - - - - - - - - - - - - - - - G - - - - | L83V | 132 | 40.00% |
| E-C109/ | G350 | - - - - - - - - - - - - - - - G - - - - | L83V | 6 | 1.82% |
| E-G110/ | G350 | - G | | | |
| E-G131/ | G350 | - G | | | |
| E-G131/ | C188/ G350 | - C | | | |
| E-A176/ | G350 | - A | | | |
| **E-A176/ | G424/ G350 | - A | | | |
| E-T182/ | G350 | - - - - - - T | | | |
| E-C182/ | G350 | - - - - - - C | | | |
| **E-C183/ | G350 | - - - - - - C | | | |
| E-G185/ | G350 | - G | | | |
| E-A188/ | G350 | - A | | | |
| E-C188/ | G350 | - C | | | |

Ortiz-Ortiz et al. Virology Journal (2015) 12:29
| Lineage AA/NA/Sublineage AA1 | Class | Subclass | Sequence | Frequency |
|-------------------------------|-------|----------|----------|-----------|
| **E-C188/ G350**              | -     | -        | -        |            |
| **E-G189/ T256/ G350**        | -     | -        | -        | 0.30%     |
| E-G257/ G350                  | -     | -        | -        | 0.30%     |
| **E-C306/ G350**              | -     | -        | -        | 0.30%     |
| E-C442/ G350                  | -     | -        | -        | 0.30%     |
| **G535/ G350**                | -     | -        | -        | 0.30%     |
| **G257/ G350**                | -     | -        | -        | 10.91%    |
| Lineage AA/NA/Sublineage AA1  | Class AA-a | Subclass | Sequence | Frequency |
| **AA-a**                      | -     | -        | -        | 10.61%    |
| AA-a                          | -     | -        | -        | 10.91%    |
| **AA-a**/ C188                 | -     | -        | -        | 10.61%    |
| Class AA-c                    | Subclass | Sequence | Frequency |
| **AA-c**                      | -     | -        | -        | 6.67%     |
| AA-c                          | -     | -        | -        | 6.07%     |
| **AA-c**/ C271                | -     | -        | -        | 0.30%     |
| **AA-c**/ C271                | -     | -        | -        | 0.30%     |
| Lineage AFR2/Sublineage Afr2a | Class Af2-a | Sequence | Frequency |
| Af2-a                         | -     | -        | -        | 0.30%     |
| **G109/ G403**                | -     | -        | -        | 0.30%     |

HPV 16 R: reference sequence. Predicted amino acid change: the amino acid numeration was done using the 151 amino acid E6 oncoprotein form as reference. Capital letters indicate polymorphisms that produce amino acid change. Lower-case letters indicate silent mutations. – Indicate no polymorphism. Italic letters indicate new polymorphisms. Italic capital letters indicate amino acid change. **Indicate new variants.
The 8 novel variants are subclasses, 6 are subclasses of class G-350, one is subclass of class AA-a and the last one is subclass of class AA-c (Table 1). E-C183/G350, E-C306/G350 and E-G535/G350 show polymorphisms that so far have not been reported. E-C183/G350 leads to the amino acid change I27T, E-C306/G350 changes K68T and E-G535/G350 does not lead to any amino acid change (Table 1).

HPV 16 E6 variants in cervical carcinoma and precursor lesions

A total of 330 samples with HPV16 were analyzed. The histology of the 91 cervical carcinoma identified 76 (83.5%) as squamous cell carcinoma (SCC), 13 (14.3%) as adenocarcinoma (ADC) and 2 (2.2%) as other epithelial tumors. The majority of cases of cervical carcinomas were found in the FIGO stage IIB (34%). Additionally, 19 samples were HSIL, 123 LSIL and 97 with non-IL (11 with inflammation and 86 with normal Pap smears).

HPV 16 AA variants were more common in ADC (46.15%) than in SCC (30.27%). AA-a variants increased their frequency according to the degree of evolution of cervical lesion: 38.46% in ADC, 15.79% in SCC, 15.79% in HSIL, 8.94% in LSIL and 3.09% in non-IL. HPV 16 E variants were the most common in SCC (69.75%), HSIL (78.94%), LSIL (87.79%) and non-IL (89.69%). HPV 16 E-G350 class was the most frequent in all groups, E-Prototype, on the other hand, was not detected in ADC and other epithelial tumors, and only 2.63% of SCC, 5.26% of HSIL, 18.7% of LSIL and 17.53% of non-IL (Table 2). The Af variants were not found in any cervical carcinoma.

Associations between the five most frequent HPV 16 E6 variants and LSIL, HSIL and cervical carcinoma were assessed (Table 3), using the HPV 16 E-Prototype as a reference. The 5 variants analyzed showed significant association with CC, but only AA-a variant showed significant association with HSIL. The HPV 16 variant that showed the most risk of developing CC was AA-a (OR
## Table 2 Distribution of HPV 16 E6 variants for diagnostic category

| Variant     | Non-IL N=97 | LSIL N=123 | HSIL N=19 | SCC N=76 | ADC N=13 | Other Epithelial Tumor N=2 | Cervical carcinoma N=91 | Total N=330 |
|-------------|-------------|------------|-----------|----------|----------|-----------------------------|------------------------|-------------|
| **E variants** |             |            |           |          |          |                             |                        |             |
| Class E-T350 | 23 (23.72%) | 23 (18.7%) | 1 (5.26%) | 4 (5.26%) | -        | -                           | 4 (4.4%)              | 51 (15.45%) |
| E-Prototype  | 17 (17.53%) | 23 (18.7%) | 1 (5.26%) | 2 (2.63%) | -        | -                           | 2 (2.2%)              | 43 (13.03%) |
| E-G131      | 6 (6.19%)   | -          | 2 (2.63%) | -        | -        | -                           | 2 (2.2%)              | 8 (2.42%)   |
| Class E-G350 | 64 (65.97%) | 85 (69.09%)| 14 (73.68%)| 49 (64.49%)| 7 (53.84%)| 1 (50.0%)                   | 57 (62.65%)           | 220 (66.67%)|
| E-G350      | 39 (40.21%) | 56 (45.53%)| 6 (31.58%)| 28 (36.84%)| 3 (23.08%)| -                           | 31 (34.07%)           | 132 (40.00%)|
| E-C109/G350 | -           | 3 (2.44%)  | 1 (5.26%) | 2 (2.63%) | -        | -                           | 2 (2.2%)              | 6 (1.82%)   |
| E-G110/G350 | 1 (1.03%)   | 1 (0.81%)  | -         | -        | -        | -                           | -                     | 2 (0.61%)   |
| E-G131/G350 | 1 (1.03%)   | -          | 1 (1.32%) | -        | -        | -                           | 1 (1.1%)              | 2 (0.61%)   |
| E-G131/C188/G350 | 1 (1.03%) | 1 (0.81%)  | -         | -        | -        | -                           | 2 (0.61%)              | 2 (0.61%)   |
| E-A176/G350 | 3 (3.09%)   | 5 (4.07%)  | 1 (5.26%) | 5 (6.58%) | 2 (15.38%)| 1 (50.0%)                   | 8 (8.79%)             | 17 (5.15%)  |
| **E-A176/G424/G350** | -         | -          | -         | 1 (1.32%) | -        | -                           | 1 (1.1%)              | 1 (0.30%)   |
| E-T182/G350 | -           | 1 (0.81%)  | 1 (5.26%) | 2 (2.63%) | -        | -                           | 2 (2.2%)              | 4 (1.21%)   |
| E-C182/G350 | 1 (1.03%)   | 1 (0.81%)  | -         | -        | -        | -                           | -                     | 2 (0.61%)   |
| **E-C183/G350** | 3 (3.09%) | -          | -         | -        | -        | -                           | 3 (0.91%)             | 3 (0.91%)   |
| E-G185/G350 | 1 (1.03%)   | -          | 1 (1.32%) | -        | -        | -                           | 1 (1.1%)              | 2 (0.61%)   |
| E-A188/G350 | -           | -          | -         | 1 (1.32%) | -        | -                           | 1 (1.1%)              | 1 (0.30%)   |
| E-C188/G350 | 11 (11.34%) | 13 (10.57%)| 5 (26.32%)| 8 (10.53%)| 2 (15.38%)| -                           | 10 (10.99%)           | 39 (11.82%) |
| **E-C188/G310/G350** | 1 (1.03%) | 1 (0.81%)  | -         | -        | -        | -                           | 1 (0.81%)             | 2 (0.61%)   |
| **E-G189/T256/G350** | -         | 1 (0.81%)  | -         | -        | -        | -                           | -                     | 1 (0.30%)   |
| E-G257/G350 | -           | 1 (0.81%)  | -         | -        | -        | -                           | -                     | 1 (0.30%)   |
| **E-C306/G350** | 1 (1.03%) | -          | -         | -        | -        | -                           | -                     | 1 (0.30%)   |
| E-C442/G350 | 1 (1.03%)   | -          | -         | -        | -        | -                           | -                     | 1 (0.30%)   |
| **G535/G350** | -           | 1 (0.81%)  | -         | -        | -        | -                           | -                     | 1 (0.30%)   |
| AA variants  |             |            |           |          |          |                             |                        |             |
| Class AA-a   | 4 (4.12%)   | 11 (8.94%) | 3 (15.79%)| 12 (15.79%)| 5 (38.46%)| 1 (50.0%)                   | 18 (19.78%)           | 36 (10.91%) |
| AA-a         | 3 (3.09%)   | 11 (8.94%) | 3 (15.79%)| 12 (15.79%)| 5 (38.46%)| 1 (50.0%)                   | 18 (19.78%)           | 35 (10.61%) |
| **AA-a/C188** | 1 (1.03%) | -          | -         | -        | -        | -                           | -                     | 1 (0.30%)   |
| Class AA-c   | 6 (6.19%)   | 3 (2.44%)  | 1 (5.26%) | 11 (14.48%)| 1 (7.69%) | -                           | 12 (13.19%)           | 22 (6.67%)  |
| AA-c         | 6 (6.19%)   | 3 (2.44%)  | 1 (5.26%) | 9 (11.84%)| 1 (7.69%) | -                           | 10 (10.99%)           | 20 (6.07%)  |
Table 2 Distribution of HPV 16 E6 variants for diagnostic category (Continued)

| **AA-c/G185** | - | - | - | 1 (1.32%) | - | 1 (1.1%) | 1 (0.30%) |
|---------------|---|---|---|----------|---|----------|----------|
| AA-c/C271     | - | - | - | 1 (1.32%) | - | 1 (1.1%) | 1 (0.30%) |
| Af variants   | - | 1 (0.81%) | - | - | - | 1 (0.30%) |
| Class Af2-a   | - | 1 (0.81%) | - | - | - | - | - |
| Af2-a/C109/G403 | - | 1 (0.81%) | - | - | - | - | 1 (0.30%) |

- Indicates that the variant was not found.
Table 3 The most common HPV 16 E6 variants in women from Southern Mexico and risk of cervical carcinoma

| Variants          | Non-IL N (%) | LSIL N (%) | OR (CI 95%) P | HSIIL N (%) | OR (CI 95%) P | SCC N (%) | OR (CI 95%) P | ADC N (%) | OR (CI 95%) P | Other epithelial tumor N (%) | Cervical carcinoma N (%) | OR (CI 95%) P |
|-------------------|--------------|------------|---------------|-------------|---------------|------------|---------------|-----------|---------------|----------------------------|--------------------------|---------------|
| Class E-T350a     | 23 (23.71%)  | 23 (18.7%) | -             | 4 (5.26%)   | -             | 0 (0%)     | -             | 0 (0%)    | -             | 4 (4.40%)                                      | -                        |               |
| E-Prototype       | 17 (17.53%)  | 23 (18.7%) | 1*            | 1*          | 0 (0%)       | 1*         | 2 (2.63%)    | 1*        | 0 (0%)       | 2 (2.2%)                                      | 1*                       |               |
| Class E-G350      | 64 (65.98%)  | 85 (69.11%)| 0.97          | 3.73        | 12.66         | 2.42       | 14.12         |           |               |                             |                          |               |
|                   |              |            | 0.47-1.99     | 14 (73.68%) | 0.46-30.44    | 49 (64.47%)| 1.89-84.92   | 7 (53.85%)| 0.25-∞       | 1 (50.0%)                                    | 57 (62.65%)               | 2.19-90.97    |
|                   |              |            | 0.94          | 0.22        | 0.009         | 0.44       | 14 (73.68%) | 0.46-30.44| 49 (64.47%)  | 1.89-84.92       | 7 (53.85%)               | 0.25-∞       | 1 (50.0%)  |
|                   |              |            | E-G350        | 39 (40.21%) | 56 (45.53%)   | 0.97       | 1.74          | 13.25     | 1.01          | 2.58                                           | 0.47-2.17                | 6 (31.58%)    |
|                   |              |            | 0.47-2.17     | 6 (31.58%)  | 0.29-23.17    | 28 (36.84%)| 1.84-85.86   | 3 (23.08%)| 0.15-∞       | -                                          | 31 (34.07%)               | 2.02-87.12   |
|                   |              |            | 0.98          | 0.39        | 0.010         | 0.65       |               |           |               |                             |                          |               |
|                   |              |            | E-A176/G350   | 3 (3.09%)   | 5 (4.07%)     | 1.04       | 0.98          | 39 (40.21%)| 56 (45.53%)  | 0.97                                           | 1.74          | 13.25         |
|                   |              |            | 0.47-2.17     | 6 (31.58%)  | 0.29-23.17    | 28 (36.84%)| 1.84-85.86   | 3 (23.08%)| 0.15-∞       | -                                          | 31 (34.07%)               | 2.02-87.12   |
|                   |              |            | 0.98          | 0.39        | 0.010         | 0.65       |               |           |               |                             |                          |               |
|                   |              |            | E-C188/G350   | 11 (11.34%) | 13 (10.57%)   | 1.00       | 0.91          | 8.56      | 3.05          | 10.05          | 1.00         | 0.91          | 8.56         | 3.05          |
|                   |              |            | 0.35-2.84     | 5 (26.32%)  | 0.81-77.58    | 8 (10.53%) | 1.07-68.26   | 2 (15.38%)| 0.23-∞       | -                                          | 10 (10.99%)               | 1.39-78.92   |
|                   |              |            | 0.99          | 0.08        | 0.043         | 0.40       |               |           |               |                             |                          |               |
| Class AA-a        | 4 (4.12%)    | 11 (8.94%) | 2.18          | 12.65       | 35.21         | 21.24      | 54.51         |           |               |                             |                          |               |
|                   |              |            | 0.58-8.17     | 3 (15.79%)  | 1.02-156.20   | 12 (15.79%)| 3.87-320.39  | 5 (38.46%)| 1.75-∞       | 1 (50.0%)                                    | 18 (19.78%)               | 6.36-467.62  |
|                   |              |            | 0.25          | 0.048       | 0.002         | 0.016      |               |           |               |                             |                          |               |
| AA-a              | 3 (3.09%)    | 11 (8.94%) | 3.08          | 17.40       | 43.73         | 26.69      | 69.01         |           |               |                             |                          |               |
|                   |              |            | 0.73-13.04    | 3 (15.79%)  | 1.32-229.60   | 12 (15.79%)| 4.55-420.56  | 5 (38.46%)| 2.10-∞       | 1 (50.0%)                                    | 18 (19.78%)               | 7.57-628.96  |
|                   |              |            | 0.13          | 0.03        | 0.001         | 0.01       |               |           |               |                             |                          |               |
| Class AA-c        | 6 (6.19%)    | 3 (2.44%)  | 0.44          | 2.79        | 24.46         | 3.01       | 25.28         |           |               |                             |                          |               |
|                   |              |            | 0.10-2.06     | 1 (5.26%)   | 0.15-52.20    | 11 (14.47%)| 2.89-207.12  | 1 (7.69%) | 0.15-∞       | -                                          | 12 (13.19%)               | 3.12-204.74  |
|                   |              |            | 0.30          | 0.49        | 0.003         | 0.47       |               |           |               |                             |                          |               |
| AA-c              | 6 (6.19%)    | 3 (2.44%)  | 0.46          | 2.93        | 19.97         | 2.99       | 21.16         |           |               |                             |                          |               |
|                   |              |            | 0.10-2.15     | 1 (5.26%)   | 0.16-54.90    | 9 (11.84%) | 2.34-170.25  | 1 (7.69%) | 0.15-∞       | -                                          | 10 (10.99%)               | 2.59-172.56  |
|                   |              |            | 0.32          | 0.47        | 0.006         | 0.47       |               |           |               |                             |                          |               |
| Class AF2-a       | 0 (0%)       | 1 (0.81%)  | -             | 0 (0%)      | -             | 0 (0%)     | -             | 0 (0%)    | -             | 0 (0%)                                    |                          |               |

**a**Indicate reference category (E-Prototype).

*OR was not calculated for E-T350 class because it includes reference category (E-Prototype).

To calculate OR and CI in ADC an artificial case was created.

OR: Odds ratio adjusted for age.
et al. Virology Journal (2015) 12:29

variants were the most common, followed by AA variants. In the present study of 330 women with HPV 16 circulating over a period of 16 years, 27 variants were found; E group [8]. In the present study, the most frequently identified HPV 16 variant was E-G350 (49% each one) followed by AA (11%). In Europe it is E-G350 (44%) followed by E-Prototype (38%) and AA (6%). In Western Asia it is E-G350 (51%) followed by E-Prototype (25%) and AA (9%). In Eastern Asia it is As (42%) followed by E-Prototype (37%) and E-G350 (9%). In Oceania it is E-Prototype (38%) followed by E-G350 (29%) and As (12%) and in Africa it is Afr1 and Afr2 (62%) followed by E-Prototype (34%). In the present study, the most frequently identified HPV 16 variant was E-G350 (40%), following the E-Prototype (13.03%), E-C188/G350 (11.82%), AA-a (10.61%), AA-c (6.07%) and E-A176/G424/G350 (4.0%). In the present study, the most frequently identified HPV 16 variant was E-G350 (49%) followed by AA (42%) and E-A176/G424/G350 (40%). In the present study, the most frequently identified HPV 16 variant was E-G350 (49%) followed by AA (42%) and E-A176/G424/G350 (40%).

Discussion

The objective of this study was to document HPV 16 E6 variants circulating over a period of 16 years in women from Southern Mexico and to analyze its association with cervical carcinoma and precursor lesions. According to sequence analysis, nucleotide polymorphisms were detected and used to investigate the intratypic heterogeneity of HPV 16 in the Southern Mexican population.

It is known that the genomes of HPV 16 variants differ geographically worldwide due to evolution linked to ethnic groups and that the risk for cervical carcinoma seems to be population-dependent [5,6,8,10,26-28]. Mexico is a country with diverse ethnic origins because European immigrants mixed with various indigenous populations, in consequence current population carries HPV variant from various ethnic group [8]. In the present study of 330 women with HPV 16 sampled over a period of 16 years, 27 variants were found; E variants were the most common, followed by AA variants. Studies worldwide have found that E variants are the most prevalent worldwide (94% in Oceania, 84% in Eastern Asia, 83% in North America, 82% in Europe, 78% in Western Asia and 71% in Central and South America) with exception of Africa (36%) [9]. Tornesello, et al. (2011) showed that globally, the most prevalent variant in Central and South America (including Mexico) is E-G350 (43%) followed by AA (30%) and E-Prototype (27%). In North America it is E-Prototype and E-G350 (49% each one) followed by AA (11%). In Europe it is E-G350 (44%) followed by E-Prototype (38%) and AA (6%). In Western Asia it is E-G350 (51%) followed by E-Prototype (25%) and AA (9%). In Eastern Asia it is As (42%) followed by E-Prototype (37%) and E-G350 (9%). In Oceania it is E-Prototype (38%) followed by E-G350 (29%) and As (12%) and in Africa it is Afr1 and Afr2 (62%) followed by E-Prototype (34%). In the present study, the most frequently identified HPV 16 variant was E-G350 (40%), following the E-Prototype (13.03%), E-C188/G350 (11.82%), AA-a (10.61%), AA-c (6.07%) and E-A176/G424/G350 (4.0%). In the present study, the most frequently identified HPV 16 variant was E-G350 (49%) followed by AA (42%) and E-A176/G424/G350 (40%).

Sequence Data

The 8 novel variant sequences described in this report have been deposited in GenBank under designated accession numbers KJ465992, KJ465993, KJ465994, KJ465995, KJ465996, KJ465997, KJ465998 and KJ465999.

Follow up information shows that two with the variant E-C188/G350 evolved from non-IL to LSIL, whereas those with E-C188/G310/G350 and E-G189/T256/G350 maintain LSIL status (Table 4).

The novel HPV 16 E6 variants were found in 11 women, 6 from the center of the State of Guerrero, 2 from the coast and 3 from Northern Guerrero. These variants were found in samples taken from 1997 to 2012. The AA-a/C188 HPV 16 variant was found in non-IL cervical sample taken in 1997, AA-c/G185 variant was found in a cervical carcinoma sample taken in 1998, E-A176/G424/G350 was found in a cervical carcinoma sample taken in 2003, E-C183/G350 was found in a non-IL cervical samples taken in 2002 and 2006, E-C306/G350 was found in non-IL a cervical sample taken in 2003, E-C188/G310/G350 was found in a non-IL cervical sample taken in 2004 and an LSIL taken in 2009, E-G353/G350 was found in an LSIL cervical sample taken in 2006 and E-G189/T256/G350 variant was found in an LSIL cervical sample taken in 2008. Six novel variants were found with non-IL, 3 with LSIL and 2 with cervical carcinoma (E-A176/G350/G424 and AA-c/G185). Data from a follow up cytological diagnosis of 5 women with HPV 16 E6 novel variants were collected. Follow up information shows that two with the variant E-C188/G350 evolved from non-IL to LSIL, whereas those with E-C188/G310/G350 and E-G189/T256/G350 maintain LSIL status (Table 4).

Studies on HPV 16 variants in Mexico have shown that even in the same country its distribution is different depending on the region analyzed. The prevalence of HPV 16 variants, stratified by histological groups, from five geographical regions of Mexico (Central, North-Central, Northeastern, Southeastern and Southern) is presented in Table 5. The E variants are the most prevalent in all geographical regions in women, E-prototype in the Southeastern region and E-G350 in Central and Southern Mexico. AA variants are present in the five regions, but its prevalence is higher in the Northeastern region than in the rest of the country, although it is inhabited mostly by Europeans descendants, Mestizo and very few indigenous ethnic groups [5,8,20,21,23,29]. The State of Guerrero, located in Southern Mexico, is inhabited by Mestizo, Nahua, Mixtec, Amuzgos, Tlapanaocos and Afro-Mexicans. In this study, which is larger than our previous study [24], we found that HPV 16 E-G350 was the most common variant in all histological grades, although in ADC, the prevalence of E-G350 and AA is close. In all regions of Mexico, the prevalence of AA in ADC tends to increase in comparison to the other histological grades. Moreover, among AA variants, AA-a is more common than AA-c.

Of the 27 HPV 16 variants found in Southern Mexico in 16 years, 8 of them were new and may be considered to be variants specific to this Mexican region. Previous data suggests that HPV 16 variants with E6 sequence variation are biologically distinct and may confer
| Patient | HPV 16 E6 Novel variant | Accession number GenBank | Nucleotide change | Amino acid change (not previously reported) | Women residence (City/State region) | Diagnosis/Sampling year | Follow up Diagnosis/Year |
|---------|-------------------------|--------------------------|------------------|------------------------------------------|-----------------------------------|------------------------|-----------------------|
| 1       | E-A176/G424/G350        | KJ465994                 | G424             | -                                        | Atoyac/Coast                      | Cervical carcinoma 2003 | -                     |
| 2       | E-C183/G350             | KJ465995                 | C183             | I27T                                     | Chilpancingo/Center               | Non-IL 2002           | LSIL 2006             |
| 3       | E-C183/G350             | KJ465995                 | C183             | I27T                                     | Chilpancingo/Center               | Non-IL 2006           | LSIL 2009             |
| 4       | E-C183/G350             | KJ465995                 | C183             | I27T                                     | Chilpancingo/Center               | Non-IL 2002           | -                     |
| 5       | E-C188/G310/G350        | KJ465996                 | G310             | -                                        | Chilpancingo/Center               | Non-IL 2004           | Non-IL 2005           |
| 6       | E-C188/G310/G350        | KJ465996                 | G310             | -                                        | Chilpancingo/Center               | LSIL 2009             | LSIL 2012             |
| 7       | E-G189/T256/G350        | KJ465998                 | G189 and T256    | -                                        | Chilpancingo/Center               | LSIL 2008             | LSIL 2009             |
| 8       | E-C306/G350             | KJ465997                 | C306             | K68T                                     | Acapulco Coast                    | Non-IL 2003           | -                     |
| 9       | E-G535/G350             | KJ465999                 | G535             | -                                        | Tepecoacuilco/North               | LSIL 2006             | -                     |
| 10      | AA-a/C188               | KJ465992                 | C188             | -                                        | Iguala/North                      | Non-IL 1997           | -                     |
| 11      | AA-c/G185               | KJ465993                 | G185             | -                                        | Juchitan/North                    | Cervical carcinoma 1998 | -                     |
Table 5 Published data on HPV 16 variants distribution in cervical epithelium lesions in regions of Mexico

| Region of Mexico | State/City     | Genome region | Samples | Histology | HPV 16 E | HPV 16 E-Prototype | HPV 16 E-G350 | AA   | AA-a | AA-c | Reference                  |
|------------------|----------------|---------------|---------|-----------|---------|-------------------|---------------|------|------|------|----------------------------|
| Central          | Mexico City    | E6, L1        | 80      | SCC       | 56%     | 4%                | 52%           | 44%  | -    | -    | Berumen, et al., 2001      |
|                  |                |               | 6       | ADC       | 0%      | 0%                | 0%            | 100% | -    | -    |                            |
|                  |                |               | 20      | Non-IL    | 90%     | 5%                | 85%           | 10%  | -    | -    |                            |
| Central          | Mexico City    | E6            | 50      | SCC       | 30%     | -                 | -             | 40%  | 32%  | 8%  | Lizano, et al., 2006       |
|                  |                |               | 11      | ADC       | 55%     | -                 | -             | 45%  | 27%  | 18% |                            |
|                  |                |               | 23      | HSIL      | 74%     | -                 | -             | 26%  | 26%  | 0%  |                            |
|                  |                |               | 13      | LSIL      | 54%     | -                 | -             | 46%  | 46%  | 0%  |                            |
|                  |                |               | 16      | Non-IL    | 56%     | -                 | -             | 44%  | 44%  | 0%  |                            |
| North-Central    | San Luis Potosí| E6            | 2       | ICC       | 100%    | 50%               | 50%           | 0%   | 0%   | 0%  | López-Revilla, et al., 2009|
|                  |                |               | 9       | HSIL      | 89%     | 33%               | 56%           | 11%  | 11%  | 0%  |                            |
|                  |                |               | 27      | LSIL      | 96%     | 85%               | 11%           | 4%   | 4%   | 0%  |                            |
| Northeastern     | Nuevo León     | LCR           | 112     | Undefined | 13%     | -                 | -             | 87%  | -    | -    | Calleja-Macias, et al., 2004|
| Southeastern     | Yucatan        | E6            | 25      | IC        | 52%     | 28%               | 24%           | 44%  | -    | -    | González-Losa, et al., 2004|
| Southern         | Guerrero       | E6            | 45      | ICC       | 67%     | -                 | -             | 33%  | -    | -    | Illades-Aguiar, et al., 2010|
|                  |                |               | 10      | HSIL      | 90%     | -                 | -             | 10%  | -    | -    |                            |
|                  |                |               | 18      | LSIL      | 67%     | -                 | -             | 33%  | -    | -    |                            |
|                  |                |               | 5       | Non-IL    | 60%     | -                 | -             | 40%  | -    | -    |                            |
| Southern         | Guerrero       | E6            | 76      | SCC       | 70%     | 3%                | 64%           | 30%  | 16%  | 14% | Present study               |
|                  |                |               | 13      | ADC       | 54%     | -                 | 54%           | 46%  | 38%  | 8%  |                            |
|                  |                |               | 19      | HSIL      | 79%     | 5%                | 74%           | 21%  | 16%  | 5%  |                            |
|                  |                |               | 123     | LSIL      | 88%     | 19%               | 69%           | 11%  | 9%   | 2%  |                            |
|                  |                |               | 97      | Non-IL    | 90%     | 18%               | 66%           | 10%  | 4%   | 6%  |                            |
different pathological risks for development of squamous intraepithelial lesions and invasive cervical carcinoma. E6 specific sequence variations may modify its linkage to cellular targets changing its ability for p53 degradation, inhibiting keratinocyte differentiation, modifying signal transduction [30-34].

It was proposed that there might be a strong relation between AA variant and cervical carcinoma development [9,16,25,35,36]. Using a comparative analysis, it was found in this study that HPV 16 AA-a detection rate increased according to the severity of the cervical lesion, with a large increase in ADC. The results show that HPV 16 AA-a infection has a strong association with a high risk of CC development compared to E-Prototype. This study reinforces the proposal that HPV 16 AA-a is an oncogenic risk for cervical carcinoma progression in Mexico [5]. Similar behavior was observed in HPV 16 E-A176/G350 variant, the rate increased according severity of the cervical lesion, although frequency was less than for AA-a, and the infection is associated with a risk for development of CC compared with E-Prototype, but less than for AA-a. AA-c, E-G350 and E-C188/G350, also show association with risk for CC compared with E-Prototype, although lower than the aforementioned. The results of this study highlight the importance of identifying HPV 16 variants in the screening of clinical samples and of conducting follow up test for women with the HPV 16 AA-a variant.

According to the HPV variants found in this study, the amino acid substitutions circulating in Southern Mexico are: Q3E, R10G, Q14H, D25N, I27L, I27R I27T, L28V, E29K, E29Q, E29G, I52L, K68T, F69L, H78Y, L83V (the most frequent) and E113D. The amino acid substitutions present in the HPV 16 E6 variants in descending order of association with CC were: Q14R/H78Y/L83V (AA-a variant), D25N/L83V (E-A176/G350 variant), Q14R/I27/H78Y/L83V (AA-c variant), L83V (E-G350 variant) and E29Q/L83V (E-C188/G350 variant). Q14R/H78Y/L83V amino acid changes gender AA variants with increased oncogenic potential and more efficient evasion of the host’s immune surveillance [25,37,38]. L83V amino acid change display more efficient degradation of Bax and binding to E6AP, induces ubiquitination and degradation of p53, NFX1-91 and PDZ proteins [14,33]. D25N, I27R and E29Q amino acid changes affect E6 T cell epitope [33]. Two of the 8 novel variants found in this study had amino acid changes not previously reported: I27T in E-C183/G350 variant and K68T in E-C306/G350 variant. I27T amino acid change is located at the N-terminal domain of the E6 oncoprotein; K68T is located between zinc fingers of E6. The E-C183/G350 variant was found in women with non-IL who progressed to LSIL. The finding of this new variant could be potentially important.

It was not possible to analyze the association of novel E6 variants for the risk of developing cervical carcinoma because of the low number of positive samples; however, by having nucleotide changes may also be associated with the development of cervical carcinoma.

Conclusions
Current findings show that in 16 years, at least 27 HPV 16 E6 variants were present in Southern Mexico and 8 novel variants were found, which may be considered to be variants specific to this Mexican region. The variants more frequently found in women with cervical carcinoma are E-G350, AA-a, AA-c, E-C188/G350 and E-A176/G350. All of them are associated with the development of cervical carcinoma, however, AA-a showed the highest association. This study reinforces the proposal that HPV 16 AA-a is an oncogenic risk for cervical carcinoma progression in Mexico. This represents the largest study carried out in Mexico analyzing all classes of European and non-European variants in the whole spectrum of disease, from intraepithelial lesion-free cytology to cervical carcinoma including squamous cell carcinoma and adenocarcinoma. Further studies are needed to clarify the pathogenicity of HPV 16 E6 variants.

Methods
Samples
The database and biobank, with 7,480 cervical DNA samples collected from 1997 to 2012, of the Molecular Biomedicine and Cytopathology Laboratories at the School of Chemistry and Biology of the Autonomous University of Guerrero in Chilpancingo Guerrero, Mexico, was searched for all cervical DNA samples with HPV 16 and 330 were found in appropriate conditions for analysis. The samples were studied to investigate circulating HPV 16 variants in Southern Mexico and to do a comparative analysis between these variants and the different grades of cervical lesion.

Cervical samples came from women who were residents of State of Guerrero, seeking cytological screening or for other gynecological complaints, which attended public health centers of Acapulco, Chilpancingo, and Iguala, the three biggest cities in this state of Southern Mexico. Based on the diagnosis, samples were divided into: (1) no intraepithelial lesion (non-IL) (n = 97), (2) low-grade squamous intraepithelial lesion (LSIL) (n = 123), high-grade squamous intraepithelial lesion (HSIL) (n = 19) and (4) cervical carcinoma (CC) (n = 91). Non-IL and LSIL samples have cytological diagnosis; HSIL and CC samples have histological diagnosis. Cytological diagnosis was done according to the Bethesda System [39] and histological diagnosis according to the classification system of the International Federation of Gynecology and Obstetrics (FIGO) [40].

This study was approved by the Bioethical Committee the Autonomous University of Guerrero. Informed consent was obtained from women participants.
HPV DNA was detected and identified by three methods depending on the year of which the sample was taken and analyzed: (1) from 1997 to 2010, HPV detection was done by the MY09/11 system and typing by restriction fragment length polymorphism (RFLPs); (2) from 2005 to 2010, detection was done by general GP5+/6+ PCR system and typing by sequencing analysis [24] when samples analyzed with MY09/11 PCR were negative; (3) from 2010 to 2012 HPV was detected and typed with INNO Lipa genotyping Extra (Innogenetics) [41].

HPV variants
The HPV 16 E6 gene was amplified using type-specific primers E6-F048 (5′ GAACCGAAACCGGTTAGTAT3′) and E6-R622 (5′ CAGTTGTCTCTGGTTGCAA3′) that amplify a 575-bp region [19]. PCR amplification was carried out in a 50 μl reaction containing 1 μM of each primer, 4 mM of MgCl2, and 1.25 U of Platinum Taq DNA Polymerase (Invitrogen). The DNA amplification was done in a DNA Eppendorf AG 22331 Hamburg [24] as follows: initial denaturation at 95°C for 10 min, followed by 40 cycles of 95°C for 45 s, 57°C for 30 s, 72°C for 1.15 min, and a final extension at 72°C for 10 min.

PCR products were purified with 75% isopropanol (2–34 protocol of user manual of Applied Biosystems) and ZR DNA Sequencing Clean-up Kit™ (ZYMOC RESEARCH). These were sequenced using Big Dye Terminator Chemistry v3.1 Ready Reaction Kit (Applied Biosystems, Foster City, CA) in an automated sequencer DNA ABI Prism 310 Genetic Analyzer (Applied Biosystems, Foster City, CA) using primers previously described [19]. Sequences were analyzed with EMBOSS Stretcher of the European Institute of Bioinformatics, LALING GENSTREAM network server (http://www.ebi.ac.uk/Tools/psa/emboss_stretcher/nucleotide.html and http://embnet.vital-it.ch/software/LALIGN_form.html) and the Finch TV program respectively. Sequences were aligned with reference sequence (HPV 16R) [8]. Using the E6 sequence, HPV 16 variants were classified into lineages with their respective sublineages [12]. The sublineages were stratified in classes and subclasses [13]. When new polymorphisms were found, independent PCRs were carried out under the described conditions. The products obtained were sequenced on both strands to exclude PCR artifacts and to validate the polymorphism found and accept them as new variants.

Phylogenetic analysis
HPV 16 E6 sequences were compared by multiple sequence alignments using the CLUSTAL W method [42]. A phylogenetic tree was constructed by neighbor-joining analysis executed by MEGA 5.2 program [43].

Statistical analysis
The Chi squared test was used to compare HPV 16 variant frequencies and cervical lesion grade. Differences were considered to be statistically significant when p values were less than 0.05. Age-adjusted odds ratios and 95% confidence intervals were used to estimate associations. Data analysis and statistics were done using IBM SPSS Statistics V.22.0 and STATA V.11 softwares.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
BIA and MALV designed and supervised research. JOO identified HPV 16, analyzed HPV 16 E6 variants, and did sequence alignment and statistical analysis. JOO, ICM did phylogenetic analysis. LCAR, MAJL, and WHGE collected the samples and did cytological and histological diagnosis. JOO and BIA drafted the manuscript, HABS revised the manuscript and all authors read and approved the final manuscript.

Acknowledgements
We thank José Guadalupe Muñoz Camacho and all of the Instituto Estatal de Ciberología “Dr. Arturo Beltrán Ortega” who helped with this study at the clinic sites. We thank Miguel Ángel Rodríguez Barrera for his help in the registration of new variants in GenBank. We thank Dinorah N. Martínez-Carrillo for contributing in statistical analysis. We also thank Juan Francisco Leyva and Travis Ashworth for reviewing the English style of the article. This study was supported by grant from CONACYT, México.

Author details
1Laboratorio de Biomedicina Molecular, Unidad Académica de Ciencias Químico Biológicas, Universidad Autónoma de Guerrero, Chilpancingo, Guerrero, México. 2Laboratorio de Citopatología, Unidad Académica de Ciencias Químico Biológicas, Universidad Autónoma de Guerrero, Chilpancingo, Guerrero, México. 3Instituto Estatal de Cibernología “Dr. Arturo Beltrán Ortega”, Acapulco, Guerrero, México. 4Molecular Biology and Biochemistry, School of Biological Sciences, University of California Irvine, Irvine, CA, USA. 5Departamento de Bioquímica y Medicina Molecular, Facultad de Medicina, Universidad Autónoma de Nuevo León, Monterrey, Nuevo León, México.

Received: 9 October 2014 Accepted: 16 January 2015
Published online: 22 February 2015

References
1. Zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer. 2002;2:342–50.
2. Guan P, Howell-Jones R, Li N, Bruni L, de Sanjose S, Franceschi S, et al. Human papillomavirus types in 115,789 HPV-positive women: a meta-analysis from cervical infection to cancer. Int J Cancer. 2012;131:2349–59.
3. Peitsaro P, Johansson B, Sijtenien S. Integrated human papillomavirus type 16 is frequently found in cervical cancer precursors as demonstrated by a novel quantitative real-time PCR technique. J Clin Microbiol. 2002;40(3):886–91.
4. Gheit T, Cornet I, Clifford GM, Itner T, Munk C, Tommasino M, et al. Risks for persistence and progression by human papillomavirus type 16 variant lineages among a population-based sample of Danish women. Cancer Epidemiol Biomarkers Prev. 2011;20:1315–21.
5. Benum J, Ordoñez RM, Lazzano E, Salmerón J, Galvin SC, Estrada RA, et al. Asian-American variants of human papillomavirus 16 and risk for cervical cancer: a case–control study. J Natl Cancer Inst. 2001;93(17):1255–30.
6. Zuna RE, Moore WE, Shanesmith RP, Dunn ST, Wang SS, Schiffman M, et al. Association of HPV16 E6 variants with diagnostic severity in cervical cytology samples of 354 women in a US population. Int J Cancer. 2009;125:2609–13.
7. Schiffman M, Rodriguez AC, Chan Z, Wacholder S, Herrero R, Hildesheim A, et al. A Population-Based Prospective Study of Cervicogenic Human Papillomavirus Variant Lineages, Viral Persistence, and Cervical Neoplasia. Cancer Res. 2010;70(8):3159–69.
8. Calleja-Macias E, Kalantar M, HuH J, Ortiz-López R, Rojas-Martínez A, Gonzalez-Guerrero JF, et al. Genomic diversity of human papillomavirus-16, 18, 31 and
35 isolates in a Mexican population and relationship to European, African, and Native American variants. Virol. 2004;319:315–23.

9. Tornesello ML, Loito S, Benincasa G, Fulciniti F, Botti G, Greggi S, et al. Human papillomavirus (HPV) genotypes and HPV16 variants and risk of adenocarcinoma and squamous cell carcinoma of the cervix. Gynecol Oncol. 2011;121(1):32–42.

10. Comet I, Ghez T, Lannacone MR, Vignat J, Sylla ES, Del Mistro A, et al. HPV16 genetic variation and the development of cervical cancer worldwide. Br J Cancer. 2013;108(240–4).

11. Chen Z, Schiffman M, Herrero R, De Salle R, Anastas K, Segondy M, et al. Evolution and Taxonomic Classification of Human Papillomavirus 16 (HPV16)-Related Variant Genomes: HPV31, HPV33, HPV35, HPV52, HPV58 and HPV67. PloS One. 2011;6(5):e18083.

12. Comet I, Ghez T, Franceschi S, Vignat J, Burk RD, Sylla ES, et al. Human Papillomavirus Type 16 Genetic Variants: Phylogeny and Classification Based on E6 and LCR. J Virol. 2012;86(21):6855–61.

13. Huertas-Salgado A, Martín-Gámez DC, Moreno P, Murillo R, Bravo MM, Villa L, et al. Molecular variants of human papillomavirus HPV type 16 An updated and unified criterion for clustering and nomenclature. Virol. 2011;410(1):1–15.

14. Lichtig H, Algrisi M, Botzer LE, Abadi T, Vierbicky Z, Jackman A, et al. HPV16 E6 natural variants exhibit different activities in functional assays relevant to the carcinogenic potential of E6. Virol. 2006;350:216–27.

15. Zehbe I, Richard C, Decarlo CA, Shai A, Lambert PF, Lichtig H, et al. Human papillomavirus 16 E6 variants differ in their dysregulation of human keratinocyte differentiation and apoptosis. Virol. 2009;383:69–77.

16. Zehbe I, Lichtig H, Westerback A, Lambert PF, Tommasino M, Sherman L. Rare human papillomavirus 16 E6 variants reveal significant oncogenic potential. Mol Cancer. 2011;10:7(1):1–13.

17. Smith B, Chen Z, Reimers L, Dooris TK, Schiffman M, DeSalle R, et al. Sequence Imputation of HPV16 Genomes for Genetic Association Studies. PLoS ONE. 2011;6(6):e21375.

18. Jang M, Rhee JE, Jang DH, Kim SS. Gene Expression Profiles are Altered in Human Papillomavirus-16 E6 D25E-Expressing Cell Lines. Virol J. 2011;8(435):1–8.

19. Casas L, Galván SC, Ordoñez RM, López N, Guido M, Berumen J. Asian-American variants of human papillomavirus type 16 have extensive mutations in the E2 gene and are highly amplified in cervical carcinomas. Int J Cancer. 1999;83(4):449–55.

20. Lizano M, Berumen J, García-Carranca A. HPV-related Carcinogenesis: Basic Concepts, Viral Types and Variants. Arch Med Res. 2009;40(6):428–34.

21. López-Revilla R, Pineda MA, Ortíz-Revilla J, Ortíz-Ortiz F, Villa L, et al. Human papillomavirus type 16 variant analysis in glandular and squamous intraepithelial lesions, and invasive carcinoma in San Luis Potosí City, Mexico. Infectious Agents and Chronic Disorders. 2008;1(1):30–9.

22. Zehbe I, Mytilineos J, Wikström I, Henriksen R, Edler L, Tommasino M, Aghamolaii M, Rattanachaikulsri S, et al. Association between human papillomavirus 16 E6 variants and human leukocyte antigen class I polymorphism in cervical cancer of Swedish women. Hum Immunol. 2003;64(5):538–42.

23. Sichero L, Sobrinho JS, Villa LL. Oncogenic potential diverge among human papillomavirus type 16 natural variants. Virol. 2012;452:127–32.

24. Solomon D, Davey D, Kurman R, Moriaty A, O’Connor D, Prey M, et al. The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA. 2002;287:2114–9.

25. Benedit JL. FIGO staging classifications and clinical practice guidelines of gynecologic cancers. FIGO Committee on Gynecologic Oncology. Int J Gynecol Obstet. 2000;69:209–62.

26. Mier B, van Doorn LJ, Schauwerw J, Molijn A, Sastrowijoto S, ter Schegget J, et al. Hybridization line probe assay for detection and identification of anogenital HPV genotypes and HPV16 variant analysis in glandular and squamous neoplastic lesions of the uterine cervix. Gynecol Oncol. 2010;117(2):297–301.

27. Zehbe I, Mytilineos J, Wilskróm I, Henriksen R, Edler L, Tommasino M. Association between human papillomavirus 16 E6 variants and human leukocyte antigen class I polymorphism in cervical cancer of Swedish women. Hum Immunol. 2003;64(5):538–42.

28. Sichero L, Sobrinho JS, Villa LL. Oncogenic potential diverge among human papillomavirus type 16 natural variants. Virol. 2012;452:127–32.

29. Solomon D, Davey D, Kurman R, Moriaty A, O’Connor D, Prey M, et al. The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA. 2002;287:2114–9.

30. Zehbe I, Voglino G, Wilander E, Delius H, Marongiu A, Edler L, et al. p53 codon 72 polymorphism and various human papillomavirus 16 E6 genotypes are risk factors for cervical cancer development. Cancer Res. 2001;61(2):608–11.

31. Xi LF, Kouyts LA, Hildesheim A, Galloway DA, Wheeler CM, Winer RL, et al. Risk for High-Grade Cervical Intraepithelial Neoplasia Associated with Variants of Human Papillomavirus Types 16 and 18. Cancer Epidemiol Biomarkers Prev. 2007;16:4–10.

32. Chopitt P, Elakasakanan T, Pintong C, Kongyongyoes B, Kleeblao P, Chairoensri N. Prevalence of human papillomavirus type 16 and its variants in abnormal squamous cervical cells in Northeast Thailand. Int J Infect Dis. 2009;13(2):12–9.

33. Pillai MR, Harithan R, Babu JM, Lakshmi S, Chipulkar SV, Parkar M, et al. Molecular variants of HPV-16 associated with cervical cancer in Indian population. Int J Cancer. 2009;125(1):91–103.

34. Wise-Diaper TM, Wells SL. Papillomavirus E6 and E7 proteins and their cellular targets. Front Biosci. 2008;13:1003–17.

35. Junes-Gill K, Sichero L, Maciag PC, Melto W, Noronha V, Villa LL. Human papillomavirus type 16 variants in cervical cancer from an admixed population in Brazil. J Med Virol. 2008;80(9):1639–45.

36. Quint KD, de Koning MN, van Doorn LJ, Quint WG, Prog EC. HPV genotyping and HPV16 variant analysis in glandular and squamous neoplastic lesions of the uterine cervix. Gynecol Oncol. 2010;117(2):297–301.

37. Zehbe I, Mytilineos J, Wikström I, Henriksen R, Edler L, Tommasino M. Aghamolaii M, Rattanachaikulsri S, et al. Association between human papillomavirus 16 E6 variants and human leukocyte antigen class I polymorphism in cervical cancer of Swedish women. Hum Immunol. 2003;64(5):538–42.

38. Sichero L, Sobrinho JS, Villa LL. Oncogenic potential diverge among human papillomavirus type 16 natural variants. Virol. 2012;452:127–32.

39. Solomon D, Davey D, Kurman R, Moriaty A, O’Connor D, Prey M, et al. The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA. 2002;287:2114–9.

40. Zehbe I. Molecular Evolutionary Genetics Analysis using Maximum Likelihood, alignment aided by quality analysis tools. Nucleic Acids Res. 1997;25(19):4876–82.

41. Tamura K, Peterson D, Peterson N, Stecher G, Nei M, Kumar S. MEGA5: Molecular Evolutionary Genetics Analysis using Maximum Likelihood, Evolutionary Distance, and Maximum Parsimony Methods. Mol Biol Evol. 2011;28(10):2731–9.